> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Patent Infringement Notice on Alvotech Biosimilar BLA
- URL: https://www.fdaweb.com/patent-infringement-notice-on-alvotech-biosimilar-bla/
- Published: 2022-02-10T12:00:00.000Z
- Updated: 2026-09-14T17:32:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151134

*Federal Register* notice: FDA is posting notice that a BLA applicant for a biosimilar product has notified the agency that an action for patent infringement was filed in connection with the applicant’s BLA. FDA is required to publish notice of any complaint received under Section 351(l)(6)(C) of the PHS Act. The notice the agency received concerned AbbVie Inc. and AbbVie Biotechnology Ltd. v. Alvotech HF — 1:21–cv–02258 (Northern IL District, filed 4/27/2021). To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-02-10/pdf/2022-02799.pdf?ref=fdaweb.com).